Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood

Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained r...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1253279
Main Authors Günther, Claudia, Wolf, Christine, Fennen, Louisa, Rösing, Sarah, Beissert, Stefan, Aringer, Martin, Lee-Kirsch, Min Ae
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 21.09.2023
Subjects
anifrolumab
CLASI
cutaneous lupus
IFN score
Immunology
interferon
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2023.1253279

Cover

More Information
Summary:Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained remission of previously refractory CLE lesions, beginning within the first weeks of treatment. Decline in CLASI-A score was paralleled by a reduction in IFN score determined by mRNA expression of seven IFN-stimulated genes (ISGs) in blood. These data suggest that a subset of ISGs could be a valuable biomarker in CLE.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Edited by: Dario Roccatello, University of Turin, Italy
Reviewed by: Giovanni Maria Rossi, University Hospital of Parma, Italy; Bobby Kwanghoon Han, University of Washington, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1253279